Cancer Database Query Results

Scientific Papers found: Click to Expand⟱
3897- MCT,    The medium-chain fatty acid decanoic acid reduces oxidative stress levels in neuroblastoma cells
- in-vitro, AD, NA
*ROS↓, *H2O2↓,
3896- MCT,    Improvement of Main Cognitive Functions in Patients with Alzheimer's Disease after Treatment with Coconut Oil Enriched Mediterranean Diet: A Pilot Study
- Trial, AD, NA
*memory↑, *cognitive↑,
3895- MCT,    How does coconut oil affect cognitive performance in alzheimer patients?
- Human, AD, NA
*cognitive↑,
2500- meben,    Antiparasitic mebendazole shows survival benefit in 2 preclinical models of glioblastoma multiforme
- in-vitro, GBM, U87MG - in-vivo, GBM, NA
α-tubulin↓, AntiCan↑, TumCG↓, OS↑, VEGF↓, Hif1a↓,
1899- MeJa,    Methyl jasmonate induces production of reactive oxygen species and alterations in mitochondrial dynamics that precede photosynthetic dysfunction and subsequent cell death
- in-vitro, NA, NA
ROS↑, MMP↓, eff↓, H2O2?,
1898- MeJa,    Methyl jasmonate and its potential in cancer therapy
- Review, Var, NA
ROS↑, selectivity↑, toxicity↝,
1775- MEL,  Chemo,  Rad,    A Systematic Review of the Chemo/Radioprotective Effects of Melatonin against Ototoxic Adverse Effects Induced by Chemotherapy and Radiotherapy
- Review, Var, NA
chemoP↑, radioP↑, antiOx↑, Inflam↑,
1776- MEL,    Therapeutic strategies of melatonin in cancer patients: a systematic review and meta-analysis
- Review, NA, NA
Remission↑, OS↑, neuroP↑, VEGF↓, KISS1↑, TumCP↓, ChemoSideEff↓, radioP↑, Dose∅, *ROS↓, DNArepair↑, ROS↑,
1783- MEL,    The efficacy and safety of melatonin in concurrent chemotherapy or radiotherapy for solid tumors: a meta-analysis of randomized controlled trials
- Review, Var, NA
Dose∅, Remission↑, OS↑, radioP↑,
1786- MEL,    What is known about melatonin, chemotherapy and altered gene expression in breast cancer (Review)
- Review, NA, NA
AntiTum↑, Risk↓, ChemoSen↑,
1785- MEL,    Antitumoral melatonin-loaded nanostructured lipid carriers
- in-vitro, Var, NA
selectivity↑, TumCD↑,
1784- MEL,    Melatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta-analysis of randomized trials
- Review, NA, NA
Remission↑,
1782- MEL,    Melatonin in Cancer Treatment: Current Knowledge and Future Opportunities
- Review, Var, NA
AntiCan↑, Apoptosis↑, TumCP↓, TumCG↑, TumMeta↑, ChemoSideEff↓, radioP↑, ChemoSen↑, *ROS↓, *SOD↑, *GSH↑, *GPx↑, *Catalase↑, Dose∅, VEGF↓, eff↑, Hif1a↓, GLUT1↑, GLUT3↑, CAIX/CA9↑, P21↑, p27/CDKN1B↑, PTEN↑, Warburg↓, PI3K↓, Akt↓, NF-kB↓, cycD1/CCND1↓, CDK4↓, CycB/CCNB1↓, CDK4↓, MAPK↑, IGF-1R↓, STAT3↓, MMP9↓, MMP2↓, MMP13↓, E-cadherin↑, Vim↓, RANKL↓, JNK↑, Bcl-2↓, P53↑, Casp3↑, Casp9↑, BAX↑, DNArepair↑, COX2/PTGS2↓, IL6↓, IL8↓, NO↓, T-Cell↑, NK cell↑, Treg lymp↓, FOXP3↓, CD4+↑, TNF-α↑, Th1 response↑, BioAv↝, RadioS↑, OS↑,
1781- MEL,    Melatonin in patients with cancer receiving chemotherapy: a randomized, double-blind, placebo-controlled trial
- Trial, Lung, NA
QoL↑, OS∅, selectivity↑,
1780- MEL,    Utilizing Melatonin to Alleviate Side Effects of Chemotherapy: A Potentially Good Partner for Treating Cancer with Ageing
- Review, Var, NA
*antiOx↑, *toxicity↓, ChemoSen↑, *eff↑, *mitResp↑, *ATP↑, *ROS↓, *CardioT↓, *GSH↑, *NOS2↓, *lipid-P↓, eff↑, *HO-1↑, *NRF2↑, *NF-kB↑, TumCP↓, eff↑, neuroP↑,
1779- MEL,    Therapeutic Potential of Melatonin Counteracting Chemotherapy-Induced Toxicity in Breast Cancer Patients: A Systematic Review
- Review, BC, NA
QoL↑, OS↑, Dose∅, antiOx↑, ROS↑, SOD↑, Catalase↑, GPx↑, Risk↓, NK cell↑, IL1β↓, IL6↓, TNF-α↓, radioP↑, chemoP↑, TumVol↓, TumMeta↓, angioG↓, ChemoSen↑, eff↑,
1778- MEL,    Melatonin: a well-documented antioxidant with conditional pro-oxidant actions
- Review, Var, NA - Review, AD, NA
*ROS↓, *antiOx↓, ROS↑, selectivity↑, Dose↑, *mitResp↑, *ATP↑, *ROS↓, eff↑, ROS↑, Dose↑, *toxicity∅, ROS↑, eff↓, ROS↝, Dose↑, other↑,
1777- MEL,    Melatonin as an antioxidant: under promises but over delivers
- Review, NA, NA
*ROS↓, *Fenton↓, *antiOx↑, *toxicity∅, *GPx↑, *GSR↑, *GSH↑, *NO↓, *Iron↓, *Copper↓, *IL1β↓, *iNOS↓, *Casp3↓, *BBB↑, *RenoP↑, chemoP↑, *Ca+2↝, eff↑, *PKCδ?, ChemoSen↑, eff↑, Akt↓, DR5↑, selectivity↑, ROS↑, eff↑,
7495- MEL,    Melatonin: a promising neuroprotective agent for cerebral ischemia-reperfusion injury
- Review, Stroke, NA
*other↓, *neuroP↑, *Stroke↓, *Dose↝, *Risk↓, *cognitive↑,
7494- MEL,  Sul,    Medical and surgical treatments for tinnitus: the efficacy of combined treatment with sulodexide and melatonin
- Trial, Nor, NA
*Dose↝, *Tinn↓, *AntiThr↑,
7493- MEL,    Effect of melatonin supplementation on tinnitus: systematic literature review and meta-analysis Melatonin and Tinnitus
- Review, Nor, NA
*Tinn↓, *QoL↑,
6419- MEL,    The potential influence of melatonin on mitochondrial quality control: a review
- Review, Nor, NA
*mt-ACC⇅, *PKM1↑, *PKM2↑, *Glycolysis↝, *PDKs↑, *FAO↑, *ETC↑, *OXPHOS↑, *ATP↑, Glycolysis↓, OXPHOS↑, *Ca+2↓, *ROS↓, *antiOx↑, *SOD2↑, *GPx↑, *Catalase↑, *MFN1↑, *MFN2↑, *OPA1↑, *YAP/TEAD↑, *Hippo↑, *SIRT1↑, *PGC-1α↑, *DRP1/DNM1L↓,
6418- MEL,  RES,    Melatonin improves mitochondrial function by preventing mitochondrial fission in cadmium-induced rat proximal tubular cell injury via SIRT1-PGC-1α pathway activation
- in-vivo, AD, NA
*neuroP↑, *DRP1/DNM1L↓, *FIS1↓, *ROS↓, *MMP↑, *SIRT1↑, *PGC-1α↑, *eff↑,
995- MEL,    Melatonin Treatment Triggers Metabolic and Intracellular pH Imbalance in Glioblastoma
- vitro+vivo, GBM, NA
LDHA↓, MCT4↓, lactateProd↓, i-pH↓, ROS↑, ATP↓, TumCD↑, TumCCA↑, PDH↓, Glycolysis↓, GlucoseCon↓, TumCG↓,
971- MEL,    Melatonin down-regulates HIF-1 alpha expression through inhibition of protein translation in prostate cancer cells
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3 - in-vitro, Pca, LNCaP
Hif1a↓, VEGF↓, p‑p70S6↓,
1063- MEL,    HDAC1 inhibition by melatonin leads to suppression of lung adenocarcinoma cells via induction of oxidative stress and activation of apoptotic pathways
- in-vitro, Lung, A549 - in-vitro, Lung, PC9
AntiCan↑, TumCMig↓, GSH↓, Casp3↑, Apoptosis↑, ROS↑, HDAC1↓, Ac-histone H3↑, PUMA↑, BAX↑, PCNA↓, Bcl-2↓,
1042- MEL,    Melatonin Downregulates PD-L1 Expression and Modulates Tumor Immunity in KRAS-Mutant Non-Small Cell Lung Cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H460 - in-vitro, Lung, LLC1
PD-L1↓, YAP/TEAD↓, TAZ↓, TumCG↓,
4705- MEL,    Melatonin: beyond circadian regulation - exploring its diverse physiological roles and therapeutic potential
- Review, Nor, NA
*CLOCK↝, *BMD↑, *cardioP↑, *neuroP↑, *Sleep↑,
6541- MeSal,    Toxicology Answer: Oil of Wintergreen
- Review, Nor, NA
*Inflam↓, *Pain↓, *BioAv↝, *BloodF↑, *toxicity↑,
6540- MeSal,    Sodium salicylate induces apoptosis in HCT116 colorectal cancer cells through activation of p38MAPK
- in-vitro, CRC, HCT116
Apoptosis↑, p38↑, MAPK↑,
6539- MeSal,    Sodium salicylate induces apoptosis via p38 mitogen-activated protein kinase but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation
- in-vitro, Nor, NA
*NF-kB↓, *ERK↓,
6538- MeSal,  ASA,    Salicylate induces AMPK and inhibits c-MYC to activate a NRF2/ARE/miR-34a/b/c cascade resulting in suppression of colorectal cancer metastasis
- in-vitro, CRC, NA
chemoPv↑, AMPK↑, NRF2↑, miR-34a↑, cMyc↓, tumCV↓, Apoptosis↑, TumCI↓, TumCMig↓, MET↑,
6537- MeSal,    The ancient drug salicylate directly activates AMP-activated protein kinase
- Review, Nor, NA
*BioAv↝, *AMPK↑, *Half-Life↝,
6536- MeSal,    Salicylates inhibit NF-kappaB activation and enhance TNF-alpha-induced apoptosis in human pancreatic cancer cells
- in-vitro, PC, PANC1 - in-vitro, PC, Bxpc-3
p‑IKKα↓, Apoptosis↑, DNAdam↑, NF-kB↓,
6535- MeSal,    Phytochemistry and Biological Profile of Gaultheria procumbens L. and Wintergreen Essential Oil: From Traditional Application to Molecular Mechanisms and Therapeutic Targets
*Inflam↓, *antiOx↑, *AntiBio↑, *other↝,
6534- MeSal,    Volatile Constituent Analysis of Wintergreen Essential Oil and Comparison with Synthetic Methyl Salicylate for Authentication
- Study, Nor, NA
*Bacteria↓, *other↝,
1204- MET,    Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer
- in-vitro, Lung, A549 - in-vitro, Lung, H1299
MDA↑, ROS↑, Iron↑, GSH↓, T-SOD↓, Catalase↓, GPx4↓, xCT/SLC7A11↓, NRF2↓, HO-1↓,
1066- MET,    Metformin increases PDH and suppresses HIF-1α under hypoxic conditions and induces cell death in oral squamous cell carcinoma
- in-vitro, SCC, NA
PDH↑, Hif1a↓, TumCMig↓, Casp3↑, P53∅,
1043- MET,  immuno,    Metformin reduces PD-L1 on tumor cells and enhances the anti-tumor immune response generated by vaccine immunotherapy
- in-vitro, NA, NA
eff↑, PD-L1↓, Ki-67↑, TIM-3↑, L-sel↑,
994- MET,    Tumor metabolism destruction via metformin-based glycolysis inhibition and glucose oxidase-mediated glucose deprivation for enhanced cancer therapy
- in-vitro, Var, NA
Glycolysis↓, HK2↓, ATP↓, AMPK↑, P53↑, Warburg↓, Apoptosis↑,
970- MET,    Metformin suppresses HIF-1α expression in cancer-associated fibroblasts to prevent tumor-stromal cross talk in breast cancer
CAFs/TAFs↝, p‑AMPK↑, PHDs↑, Hif1a↓, TumCI↓,
5803- MET,  carbop,    Metformin, at Concentrations Corresponding to the Treatment of Diabetes, Potentiates the Cytotoxic Effects of Carboplatin in Cultures of Ovarian Cancer Cells
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, SKOV3
eff↑, ChemoSen↑, TumCCA↑,
5804- MET,  NIV,    Durable Response to Nivolumab Combined With Metformin in Advanced Pancreatic Cancer: A Case Report With Seven Years of Follow-Up.
- Case Report, PC, NA
OS↑, Dose↝,
5785- MET,    Metformin improves healthspan and lifespan in mice
- in-vivo, Nor, NA
*AntiDiabetic↑, *AntiAge↑, *toxicity⇅, *CRM↑, *Strength↑, *LDL↓, *AMPK↑, *TAC↑, *ROS↓, *Inflam↓, Risk↓, *cardioP↑, *ALAT↓, *NRF2↑, *SOD2↑, *TrxR1↑, *NQO1↑, *NQO2↑,
5796- MET,    Tumor, whole blood, plasma, and tissue concentrations of metformin in lung cancer patients
- Human, Lung, NA
selectivity↑, AMPK↑, Risk↓, Half-Life↝, ChemoSen↑,
5795- MET,    Metformin: A Review of Potential Mechanism and Therapeutic Utility Beyond Diabetes
- Review, AD, NA - Review, Park, NA - Review, Diabetic, NA
*AntiDiabetic↑, *AMPK↑, *glyC↓, *ROS↓, *cardioP↑, *neuroP↑, *Half-Life↝, *toxicity↝, *BioAv↑, *glucose↓, *AGEs↓, AntiCan↑, Risk↓, TumCP↓, Apoptosis↑, TumCCA↑, cycD1/CCND1↓, pRB↓, p27/CDKN1B↓, mTOR↓, Casp↑, ROS↑, MMP↓, ChemoSen↑, *hepatoP↑, *CRM↑, *Insulin↓,
5800- MET,    Metformin as anticancer agent and adjuvant in cancer combination therapy: Current progress and future prospect
- Review, Var, NA
ChemoSen↑, RadioS↑, Imm↑, *AntiDiabetic↑, *AMPK↑, TumCP↓, hepatoP↑, ATP↓, AMP↑, glucoNG↓, ROS↑, compI↓, DNAdam↑, CSCs↓, NP/CIPN↓, chemoP↑, toxicity↓, Trx↓, eff↑, cycD1/CCND1↓, CDK4↓, CDK6↓, cycE/CCNE↓, CDK2↓,
2456- MET,    Direct inhibition of hexokinase activity by metformin at least partially impairs glucose metabolism and tumor growth in experimental breast cancer
- in-vitro, BC, MDA-MB-231 - in-vivo, NA, NA
GlucoseCon↓, TumCG↓, HK2↓, p‑AMPK↑, TXNIP↓, *toxicity↓,
2457- MET,    Metformin Impairs Glucose Consumption and Survival in Calu-1 Cells by Direct Inhibition of Hexokinase-II
- in-vitro, Lung, Calu-1
HK1↓, HK2↓, GlucoseCon↓, MMP↓, ATP↓,
2493- MET,    Metformin Inhibits Gluconeogenesis by a Redox-Dependent Mechanism In Vivo
- in-vivo, Nor, NA
glucoNG↓, glucose↓,

Showing Research Papers: 5701 to 5750 of 8269
Prev Page 115 of 166 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 8269

Pathway results for Effect on Cancer / Diseased Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↑, 2,   Catalase↓, 1,   Catalase↑, 1,   compI↓, 1,   GPx↑, 1,   GPx4↓, 1,   GSH↓, 2,   H2O2?, 1,   HK1↓, 1,   HO-1↓, 1,   Iron↑, 1,   MDA↑, 1,   NRF2↓, 1,   NRF2↑, 1,   OXPHOS↑, 1,   ROS↑, 13,   ROS↝, 1,   SOD↑, 1,   T-SOD↓, 1,   Trx↓, 1,   xCT/SLC7A11↓, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↓, 4,   MMP↓, 3,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

Ac-histone H3↑, 1,   AMP↑, 1,   AMPK↑, 3,   p‑AMPK↑, 2,   CAIX/CA9↑, 1,   cMyc↓, 1,   glucoNG↓, 2,   glucose↓, 1,   GlucoseCon↓, 3,   Glycolysis↓, 3,   HK2↓, 3,   lactateProd↓, 1,   LDHA↓, 1,   MCT4↓, 1,   PDH↓, 1,   PDH↑, 1,   Warburg↓, 2,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   Apoptosis↑, 7,   BAX↑, 2,   Bcl-2↓, 2,   Casp↑, 1,   Casp3↑, 3,   Casp9↑, 1,   DR5↑, 1,   JNK↑, 1,   MAPK↑, 2,   p27/CDKN1B↓, 1,   p27/CDKN1B↑, 1,   p38↑, 1,   PUMA↑, 1,   TumCD↑, 2,   YAP/TEAD↓, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

p‑p70S6↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

KISS1↑, 1,   other↑, 1,   pRB↓, 1,   tumCV↓, 1,  

DNA Damage & Repair(tgid=10) ⓘ

DNAdam↑, 2,   DNArepair↑, 2,   P53↑, 2,   P53∅, 1,   PCNA↓, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK2↓, 1,   CDK4↓, 3,   CycB/CCNB1↓, 1,   cycD1/CCND1↓, 3,   cycE/CCNE↓, 1,   P21↑, 1,   TumCCA↑, 3,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CSCs↓, 1,   HDAC1↓, 1,   IGF-1R↓, 1,   miR-34a↑, 1,   mTOR↓, 1,   PI3K↓, 1,   PTEN↑, 1,   STAT3↓, 1,   TAZ↓, 1,   TumCG↓, 4,   TumCG↑, 1,  

Migration(tgid=13) ⓘ

CAFs/TAFs↝, 1,   E-cadherin↑, 1,   Ki-67↑, 1,   L-sel↑, 1,   MET↑, 1,   MMP13↓, 1,   MMP2↓, 1,   MMP9↓, 1,   Treg lymp↓, 1,   TumCI↓, 2,   TumCMig↓, 3,   TumCP↓, 5,   TumMeta↓, 1,   TumMeta↑, 1,   TXNIP↓, 1,   Vim↓, 1,   α-tubulin↓, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   Hif1a↓, 5,   NO↓, 1,   PHDs↑, 1,   VEGF↓, 4,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↑, 1,   GLUT3↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD4+↑, 1,   COX2/PTGS2↓, 1,   FOXP3↓, 1,   p‑IKKα↓, 1,   IL1β↓, 1,   IL6↓, 2,   IL8↓, 1,   Imm↑, 1,   Inflam↑, 1,   NF-kB↓, 2,   NK cell↑, 2,   PD-L1↓, 2,   T-Cell↑, 1,   Th1 response↑, 1,   TNF-α↓, 1,   TNF-α↑, 1,  

Cellular Microenvironment(tgid=17) ⓘ

i-pH↓, 1,   TIM-3↑, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6↓, 1,   RANKL↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↝, 1,   ChemoSen↑, 9,   Dose↑, 3,   Dose↝, 1,   Dose∅, 4,   eff↓, 2,   eff↑, 11,   Half-Life↝, 1,   RadioS↑, 2,   selectivity↑, 6,  

Clinical Biomarkers(tgid=22) ⓘ

IL6↓, 2,   Ki-67↑, 1,   PD-L1↓, 2,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 4,   AntiTum↑, 1,   chemoP↑, 4,   chemoPv↑, 1,   ChemoSideEff↓, 2,   hepatoP↑, 1,   neuroP↑, 2,   NP/CIPN↓, 1,   OS↑, 6,   OS∅, 1,   QoL↑, 2,   radioP↑, 5,   Remission↑, 3,   Risk↓, 5,   toxicity↓, 1,   toxicity↝, 1,   TumVol↓, 1,  
Total Targets: 158

Pathway results for Effect on Normal Cells:


NA, unassigned(tgid=0) ⓘ

AntiBio↑, 1,   Stroke↓, 1,   Tinn↓, 2,  

Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 4,   Catalase↑, 2,   Copper↓, 1,   Fenton↓, 1,   GPx↑, 3,   GSH↑, 3,   GSR↑, 1,   H2O2↓, 1,   HO-1↑, 1,   Iron↓, 1,   lipid-P↓, 1,   MFN1↑, 1,   MFN2↑, 1,   NQO1↑, 1,   NRF2↑, 2,   OPA1↑, 1,   OXPHOS↑, 1,   ROS↓, 11,   SOD↑, 1,   SOD2↑, 2,   TAC↑, 1,   TrxR1↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

ATP↑, 3,   DRP1/DNM1L↓, 2,   ETC↑, 1,   FIS1↓, 1,   Insulin↓, 1,   mitResp↑, 2,   MMP↑, 1,   PGC-1α↑, 2,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

mt-ACC⇅, 1,   ALAT↓, 1,   AMPK↑, 4,   CRM↑, 2,   FAO↑, 1,   glucose↓, 1,   glyC↓, 1,   Glycolysis↝, 1,   LDL↓, 1,   PDKs↑, 1,   PKM1↑, 1,   PKM2↑, 1,   SIRT1↑, 2,  

Cell Death(tgid=5) ⓘ

Casp3↓, 1,   Hippo↑, 1,   iNOS↓, 1,   YAP/TEAD↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 1,   other↓, 1,   other↝, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

NQO2↑, 1,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

CLOCK↝, 1,   ERK↓, 1,  

Migration(tgid=13) ⓘ

Ca+2↓, 1,   Ca+2↝, 1,   PKCδ?, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Barriers & Transport(tgid=15) ⓘ

BBB↑, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   Inflam↓, 3,   NF-kB↓, 1,   NF-kB↑, 1,  

Protein Aggregation(tgid=19) ⓘ

AGEs↓, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   BioAv↝, 2,   Dose↝, 2,   eff↑, 2,   Half-Life↝, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ALAT↓, 1,   BloodF↑, 1,   BMD↑, 1,   NOS2↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiAge↑, 1,   AntiDiabetic↑, 3,   cardioP↑, 3,   CardioT↓, 1,   cognitive↑, 3,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 4,   Pain↓, 1,   QoL↑, 1,   RenoP↑, 1,   Risk↓, 1,   Sleep↑, 1,   Strength↑, 1,   toxicity↓, 2,   toxicity↑, 1,   toxicity⇅, 1,   toxicity↝, 1,   toxicity∅, 2,  

Infection & Microbiome(tgid=24) ⓘ

Bacteria↓, 1,  
Total Targets: 96

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page